Blood: Myc's Prognosis for HIV-NHLs treated with EPOCH-Vorinostat

EPOCH is the preferred option for HIV-NHLs, usually EBV plus or HHV-8 plusHistone deacetylase (HDAC) inhibitor Volinol interferes with the incubation period of EBV/HHV-8, enhances chemotherapy-induced cell death, and may clear THE HIV hostto assess whether Volino can enhance EPOCH efficacy and/or HIV removal rates, the researchers conducted a randomized Phase 2 trial that recruited 90 aggressive HIV-NHLs patients to dose-corrected EPOCH (combined with litoxil resistance if CD20 plus) or EPOCH combined voolinota (300 mg) therapySystem chemotherapy is allowed up to one cycle in advanceThe primary endpoint is Total Mitigation (CR)epOCH therapy and EPOCH combined with Volinol (1 people) were 74% and 68%, respectively, in 86 assessable percemeable large B-cell lymphoma (61 people), plasma-like lymphoma (15 people), primary fluid lymphoma (7), unclassified B-cell NHL (2 people) and Burkitt lymphoma (1 person)The CR rate was lower in patients with CD4-plus count 200 cells/mm3epOCH-Volino did not eliminate HIV host compared to single EPOCH, and led to more frequent tetrasted neutrophil reduction and thrombocytulromate reductionthe overall and event-free survival rate (EFS) of the treatment arm was similarOverall, the EFS was lower in myc-DLBCL patients (3-year EFS: 44 percent; compared to 83 percent for Myc-DLBCL)Short diagnostic-treatment intervals (DTI) are also associated with poor prognosis, while pre-protocol therapy has no negative effects, EPOCH has a wide range of effects on highly invasive HIV-NHLs, while Volino has no benefit; Myc-driven DLBCL, low CD4, and low DTI have poorer prognosis